The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...
Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback